钙尔奇D仙灵骨葆胶囊及阿仑膦酸钠片三联治疗老年骨质疏松临床疗效与安全性分析  

作　　者：符楚迪[1] 张弢[1] 董千峰 

机构地区：[1]杭州中国人民解放军第一一七医院骨科中心,310013

出　　处：《浙江临床医学》2016年第12期2193-2195,共3页Zhejiang Clinical Medical Journal

摘　　要：目的观察钙尔奇D、仙灵骨葆胶囊及阿仑膦酸钠片三联治疗老年骨质疏松的临床疗效及安全性。方法以2013年1月至2014年1月收治的300例老年骨质疏松患者为观察对象，随机分为观察组及对照组，每组各150例。两组均给予钙尔奇D联合阿仑膦酸钠片治疗，观察组在此基础上加用仙灵骨葆胶囊。比较两组患者临床疗效、不良反应及治疗前后骨密度、血清指标变化。结果两组患者治疗后3个月、6个月骨密度较治疗前均显著升高，观察组升高更为明显，差异均有统计学意义（P〈0．05）。观察组临床总有效率为90．7％，显著高于对照组的74．7％（P〈0．05）。观察组治疗后12周血清磷（P）、钙（Ca）水平显著升高，碱性磷酸酶（AKP）水平显著降低，差异有统计学意义（P〈0．05），对照组治疗前后血清学检测结果无明显变化（P〉0．05）。观察组不良反应发生率2．0％，对照组不良反应发生率3．3％，两组患者不良反应发生率比较，差异无统计学意义（P〉0．05）。结论钙尔奇D、仙灵骨葆胶囊及阿仑膦酸钠片能够显著改善老年骨质疏松患者临床症状及骨密度，有效恢复机体钙磷代谢平衡，具有良好的临床疗效及安全性，值得进一步推广。Objective To observe the clinical efficacy and safety of combined application of caltrate D, Xianling Gubao capsule and alendronate sodium tablets for treatment of senile osteoporosis. Methods 300 patients with senile osteoporosis from January 2013 to January 2014 in our hospital were selected and randomly divided into the observation group and the control, 150 cases in each group. All of the patients were given caltrate D combined with alendronate sodium tablets treatment, while patients in the control group were treated by the strategy supplementary Xianling Gubao capsule. The clinical efficacy and adverse reactions were observed, changes of bone mineral density and serum indexes before and after treatment were compared. Results Compared with the levels before treatment, the bone density in both of the two groups increased significantly after 3 months and 6 months treatment, the changes of the observation group were more obvious, the difference was statistically significant （ P〈0.05 ） . The total effective rate of the observation group was 90.7%, which was significantly higher than that in the control group of 74.7% （ P〈0.05 ） . Serum phosphorus （P） , calcium （Ca） in the observation group increased significantly, alkaline phosphatase （AKP） decreased significantly after 12 weeks treatment, the difference was statistically significant （ P〈0.05 ） . There was no significant change in the serological indexes before and after treatment in the control group （P〉0.05 ） . The incidence of adverse reactions in the obseryation group （ 2.0% ） and control group （ 3.3% ） showed no statistical difference （P〉0.05 ） . Conclusion Combined application of caltrate D, Xianling Gubao capsule and alendronate sodium tablets in treatment of patients with senile osteoporosis can significantly improve the clinical symptoms and bone density, has good clinical efficacy and safety, and it＇s worthy of further promotion.

关 键 词：钙尔奇D 仙灵骨葆胶囊 阿仑膦酸钠 老年 骨质疏松 疗效 安全性 

分 类 号：R681.05[医药卫生—骨科学]